Cardiac microvascular rarefaction in hyperthyroidism-induced left ventricle dysfunction

Microcirculation

Volumn 20, Issue 7, 2013, Pages 590-598

  Freitas, Felipe ^a   Estato, Vanessa ^a   Carvalho, Vinícius Frias ^a   Torres, Rafael Carvalho ^a   Lessa, Marcos Adriano ^a   Tibiriçá, Eduardo ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cardiac fibrosis; Experimental hyperthyroidism; Left ventricular dysfunction; Myocardial microcirculation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; LEVOTHYROXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTHYROIDISM; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SYSTOLIC HYPERTENSION; TACHYCARDIA;

CARDIAC FIBROSIS; EXPERIMENTAL HYPERTHYROIDISM; LEFT VENTRICULAR DYSFUNCTION; MYOCARDIAL MICROCIRCULATION;

ANIMALS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HYPERTHYROIDISM; MALE; MICROCIRCULATION; MYOCARDIUM; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84885412136     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12057     Document Type: Article

References (64)

1. Amaral SL, Linderman JR, Morse MM, Greene AS. Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF. Microcirculation 8: 57-67, 2001.
2. Amaral SL, Papanek PE, Greene AS. Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training. Am J Physiol Heart Circ Physiol 281: H1163-H1169, 2001.
3. Anjos-Ramos L, Carneiro-Ramos MS, Diniz GP, Martins-Silva J, Barreto-Chaves ML. Early cardiac hypertrophy induced by thyroxine is accompanied by an increase in VEGF-A expression but not by an increase in capillary density. Virchows Arch 448: 472-479, 2006.
4. Araujo AS, Diniz GP, Seibel FE, Branchini G, Ribeiro MF, Brum IS, Khaper N, Barreto-Chaves ML, Bello-Klein A. Reactive oxygen and nitrogen species balance in the determination of thyroid hormones-induced cardiac hypertrophy mediated by renin-angiotensin system. Mol Cell Endocrinol 333: 78-84, 2011.
5. Araujo AS, Ribeiro MF, Enzveiler A, Schenkel P, Fernandes TR, Partata WA, Irigoyen MC, Llesuy S, Bello-Klein A. Myocardial antioxidant enzyme activities and concentration and glutathione metabolism in experimental hyperthyroidism. Mol Cell Endocrinol 249: 133-139, 2006.
6. Araujo AS, Schenkel P, Enzveiler AT, Fernandes TR, Partata WA, Llesuy S, Ribeiro MF, Khaper N, Singal PK, Bello-Klein A. The role of redox signaling in cardiac hypertrophy induced by experimental hyperthyroidism. J Mol Endocrinol 41: 423-430, 2008.
7. Asahi T, Shimabukuro M, Oshiro Y, Yoshida H, Takasu N. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid 11: 1009-1015, 2001.
8. Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KD, Roden RL, Bohlmeyer TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Perryman MB, Bristow MR. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 95: 1193-1200, 1997.
9. Baker KM, Singer HA. Identification and characterization of guinea pig angiotensin II ventricular and atrial receptors: coupling to inositol phosphate production. Circ Res 62: 896-904, 1988.
10. Barreto-Chaves ML, Carrillo-Sepulveda MA, Carneiro-Ramos MS, Gomes DA, Diniz GP. The crosstalk between thyroid hormones and the Renin-Angiotensin System. Vascul Pharmacol 52: 166-170, 2010.
11. Basset A, Blanc J, Messas E, Hagege A, Elghozi JL. Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study. J Cardiovasc Pharmacol 37: 163-172, 2001.
12. Biondi B. Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur J Endocrinol 167: 609-618, 2012.
13. Bouhnik J, Galen FX, Clauser E, Menard J, Corvol P. The renin-angiotensin system in thyroidectomized rats. Endocrinology 108: 647-650, 1981.
14. Brandt F, Green A, Hegedus L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 165: 491-497, 2011.
15. Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 47: 1-3, 2000.
16. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364, 1990.
17. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26: 809-820, 1994.
18. Carneiro-Ramos MS, Diniz GP, Nadu AP, Almeida J, Vieira RL, Santos RA, Barreto-Chaves ML. Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Res Cardiol 105: 325-335, 2010.
19. Carneiro-Ramos MS, Silva VB, Santos RA, Barreto-Chaves ML. Tissue-specific modulation of angiotensin-converting enzyme (ACE) in hyperthyroidism. Peptides 27: 2942-2949, 2006.
20. Chen WJ, Yeh YH, Lin KH, Chang GJ, Kuo CT. Molecular characterization of thyroid hormone-inhibited atrial L-type calcium channel expression: implication for atrial fibrillation in hyperthyroidism. Basic Res Cardiol 106: 163-174, 2011.
21. Chilian WM, Wangler RD, Peters KG, Tomanek RJ, Marcus ML. Thyroxine-induced left ventricular hypertrophy in the rat. Anatomical and physiological evidence for angiogenesis. Circ Res 57: 591-598, 1985.
22. Civelek S, Seymen O, Seven A, Yigit G, Hatemi H, Burcak G. Oxidative stress in heart tissue of hyperthyroid and iron supplemented rats. J Toxicol Environ Health A 64: 499-506, 2001.
23. Csikos T, Chung O, Unger T. Receptors and their classification: focus on angiotensin II and the AT2 receptor. J Hum Hypertens 12: 311-318, 1998.
24. Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev 15: 125-132, 2010.
25. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 379: 1155-1166, 2012.
26. Fukuyama K, Ichiki T, Takeda K, Tokunou T, Iino N, Masuda S, Ishibashi M, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A. Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. Hypertension 41: 598-603, 2003.
27. Garcia SI, Alvarez AL, Porto PI, Garfunkel VM, Finkielman S, Pirola CJ. Antisense inhibition of thyrotropin-releasing hormone reduces arterial blood pressure in spontaneously hypertensive rats. Hypertension 37: 365-370, 2001.
28. Gomberg-Maitland M, Frishman WH. Thyroid hormone and cardiovascular disease. Am Heart J 135: 187-196, 1998.
29. Greene AS, Amaral SL. Microvascular angiogenesis and the renin-angiotensin system. Curr Hypertens Rep 4: 56-62, 2002.
30. Grimm D, Cameron D, Griese DP, Riegger GA, Kromer EP. Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc Res 40: 297-306, 1998.
31. Heron MI, Kolar F, Papousek F, Rakusan K. Early and late effect of neonatal hypo- and hyperthyroidism on coronary capillary geometry and long-term heart function in rat. Cardiovasc Res 33: 230-240, 1997.
32. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J 33: 2271-2782b, 2012.
33. Hong-Brown LQ, Deschepper CF. Effects of thyroid hormones on angiotensinogen gene expression in rat liver, brain, and cultured cells. Endocrinology 130: 1231-1237, 1992.
34. Hu LW, Benvenuti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol 285: R1473-R1480, 2003.
35. Kaminski GW, Makowski K, Michalkiewicz D, Kowal J, Ruchala M, Szczepanek E, Gielerak G. The influence of subclinical hyperthyroidism on blood pressure, heart rate variability and incidence of arrhythmia. Thyroid 22: 454-460, 2012.
36. Klein I. Thyroid and the heart: the intimacy is strained. Thyroid 21: 469-470, 2011.
37. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501-509, 2001.
38. Kobori H, Ichihara A, Suzuki H, Takenaka T, Miyashita Y, Hayashi M, Saruta T. Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism. Am J Physiol 273: H593-H599, 1997.
39. Kurosaka M, Suzuki T, Hosono K, Kamata Y, Fukamizu A, Kitasato H, Fujita Y, Majima M. Reduced angiogenesis and delay in wound healing in angiotensin II type 1a receptor-deficient mice. Biomed Pharmacother 63: 627-634, 2009.
40. Kuzman JA, Thomas TA, Vogelsang KA, Said S, Anderson BE, Gerdes AM. Effects of induced hyperthyroidism in normal and cardiomyopathic hamsters. J Appl Physiol 99: 1428-1433, 2005.
41. Madsen K, Marcussen N, Pedersen M, Kjaersgaard G, Facemire C, Coffman TM, Jensen BL. Angiotensin II promotes development of the renal microcirculation through AT1 receptors. J Am Soc Nephrol 21: 448-459, 2010.
42. Marchant C, Brown L, Sernia C. Renin-angiotensin system in thyroid dysfunction in rats. J Cardiovasc Pharmacol 22: 449-455, 1993.
43. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 27: 760-765, 1996.
44. Nakamura Y, Takeda T, Ishii M, Nishiyama K, Yamakada M, Hirata Y, Kimura K, Murao S. Elevation of serum angiotensin-converting enzyme activity in patients with hyperthyroidism. J Clin Endocrinol Metab 55: 931-934, 1982.
45. Picard MH, Adams D, Bierig SM, Dent JM, Douglas PS, Gillam LD, Keller AM, Malenka DJ, Masoudi FA, McCulloch M, Pellikka PA, Peters PJ, Stainback RF, Strachan GM, Zoghbi WA. American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr 24: 1-10, 2011.
46. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuss M, Rolfs A, Steffen C, Hildebrandt A, Hetzer R, Fleck E. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 91: 1461-1471, 1995.
47. Sabino B, Lessa MA, Nascimento AR, Rodrigues CA, Henriques MG, Garzoni LR, Levy BI, Tibirica E. Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis. J Cardiovasc Pharmacol 51: 402-409, 2008.
48. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423, 1993.
49. Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 93: 483-487, 2007.
50. Smallridge RC, Rogers J, Verma PS. Serum angiotensin-converting enzyme. Alterations in hyperthyroidism, hypothyroidism, and subacute thyroiditis. JAMA 250: 2489-2493, 1983.
51. Tomanek RJ, Busch TL. Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat Rec 251: 44-49, 1998.
52. Tomanek RJ, Connell PM, Butters CA, Torry RJ. Compensated coronary microvascular growth in senescent rats with thyroxine-induced cardiac hypertrophy. Am J Physiol 268: H419-H425, 1995.
53. Toyoda N, Yasuzawa-Amano S, Nomura E, Yamauchi A, Nishimura K, Ukita C, Morimoto S, Kosaki A, Iwasaka T, Harney JW, Larsen PR, Nishikawa M. Thyroid hormone activation in vascular smooth muscle cells is negatively regulated by glucocorticoid. Thyroid 19: 755-763, 2009.
54. Vargas F, Rodriguez-Gomez I, Vargas-Tendero P, Jimenez E, Montiel M. The renin-angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. J Endocrinol 213: 25-36, 2012.
55. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 88: 2849-2861, 1993.
56. Volzke H. Hyperthyroidism and mortality. J Am Coll Cardiol 49: 2228-2229; author reply 2229-2230, 2007.
57. Wang YY, Jiao B, Guo WG, Che HL, Yu ZB. Excessive thyroxine enhances susceptibility to apoptosis and decreases contractility of cardiomyocytes. Mol Cell Endocrinol 320: 67-75, 2010.
58. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991.
59. Weiss HR, Grover GJ. T4-induced cardiac hypertrophy and the perfused and total microvasculature of the heart. Can J Physiol Pharmacol 65: 1848-1855, 1987.
60. Weiss HR, Rodriguez E, Tse J. Relationship between cGMP and myocardial O2 consumption is altered in T4-induced cardiac hypertrophy. Am J Physiol 268: H686-H691, 1995.
61. Weiss HR, Tse J. Myocardial metabolic and functional responses to acetylcholine are altered in thyroxine-induced cardiac hypertrophy. Can J Physiol Pharmacol 73: 729-735, 1995.
62. Weltman NY, Wang D, Redetzke RA, Gerdes AM. Longstanding hyperthyroidism is associated with normal or enhanced intrinsic cardiomyocyte function despite decline in global cardiac function. PLoS ONE 7: e46655, 2012.
63. Wu XD, Dai DZ, Zhang QP, Gao F. Propranolol and verapamil inhibit mRNA expression of RyR2 and SERCA in L-thyroxin-induced rat ventricular hypertrophy. Acta Pharmacol Sin 25: 347-351, 2004.
64. Xiao P, Gao C, Fan J, Du H, Long Y, Yin Y. Blockade of angiotensin II improves hyperthyroid induced abnormal atrial electrophysiological properties. Regul Pept 169: 31-38, 2011.